Workflow
Proleukin®
icon
Search documents
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
GlobeNewswire News Room· 2025-05-02 20:01
Company Overview - Iovance Biotherapeutics, Inc. is focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients [3] - The company aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [3] - Iovance's product, Amtagvi®, is the first FDA-approved T cell therapy for a solid tumor indication, showcasing the company's commitment to continuous innovation in cell therapy [3] Upcoming Financial Results - Iovance will report its first quarter 2025 financial results and corporate updates on May 8, 2025 [1] - A conference call and live audio webcast will be held on the same day at 4:30 p.m. ET to discuss these results [2] Product Development and Market Position - The Iovance TIL platform has shown promising clinical data across multiple solid tumors, indicating potential for future growth [3] - The company is also involved in gene-edited cell therapy, which may enhance treatment options for cancer patients [3]